Investigation of Gastrin-releasing Peptide As a Mediator for 5'-guanidinonaltrindole-induced Compulsive Scratching in Mice

Overview

Journal Peptides

Specialty Biochemistry

Date 2010 Dec 4

PMID 21126550

Citations 18

Authors

Saadet Inan

Nae J Dun

Alan Cowan

Affiliations

Soon will be listed here.

Abstract

Gastrin-releasing peptide (GRP) has been implicated in the itch-scratch cycle. We investigated if this gut-brain-skin peptide plays a role in the compulsive, hindleg scratching of the neck of mice by 5'-guanidinonaltrindole (GNTI), the kappa opioid receptor antagonist, and in the antipruritic activity of nalfurafine, the kappa opioid agonist. Previously, we showed that GNTI (0.03-1mg/kg, s.c.) elicits dose-related scratching and that nalfurafine (0.001-0.02mg/kg, s.c.) inhibits this behavior in mice. Utilizing immunohistochemistry, GRP positive nerve fibers were detected in mouse skin and superficial layer of the dorsal horn of the spinal cord as well as GRP positive cells in the dorsal root ganglion. Pretreating mice with either a pseudopeptide GRP receptor antagonist, RC-3095 (10-30mg/kg, s.c. at -15min), or a peptide GRP receptor antagonist, [d-Phe(6)]bombesin(6-13) methyl ester (2-100nmol, i.t. at -10min), did not suppress GNTI-induced scratching. However, pretreating mice with either antagonist inhibited scratching precipitated by the GRP receptor agonist, GRP(18-27) (2nmol, i.t.). Pretreating mice with a muscarinic M(1) receptor agonist, McN-A-343 (1.5-15μg/5μl, i.t. at -10min) antagonized GNTI-induced scratching. Norbinaltorphimine (20mg/kg, i.p. at -18 to -20h), a kappa opioid antagonist, countered the antiscratch activity of nalfurafine. We conclude that (a) the GRP receptor system does not mediate GNTI-induced scratching and (b) the kappa opioid system is involved, at least in part, in the scratch suppressing activity of nalfurafine.

Citing Articles

G protein Inactivation as a Mechanism for Addiction Treatment.

Neiswanger C, Ruiz M, Kimball K, Lee J, Land B, Berndt A bioRxiv. 2025; .

PMID: 39763910 PMC: 11702588. DOI: 10.1101/2024.12.16.628727.

Role of the Novel Peptide Phoenixin in Stress Response and Possible Interactions with Nesfatin-1.

Friedrich T, Stengel A Int J Mol Sci. 2021; 22(17).

PMID: 34502065 PMC: 8431171. DOI: 10.3390/ijms22179156.

Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans.

Inan S, Cowan A Handb Exp Pharmacol. 2020; 271:275-292.

PMID: 33296031 DOI: 10.1007/164_2020_420.

Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between Agonist Bias and Pharmacological Effects.

Cao D, Huang P, Chiu Y, Chen C, Wang H, Li M ACS Chem Neurosci. 2020; 11(19):3036-3050.

PMID: 32897695 PMC: 8336721. DOI: 10.1021/acschemneuro.0c00407.

Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.

Inan S, Torres-Huerta A, Jensen L, Dun N, Cowan A Eur J Pharmacol. 2019; 864:172702.

PMID: 31568781 PMC: 6913640. DOI: 10.1016/j.ejphar.2019.172702.

References

Sun Y, Zhong-Qiu Zhao , Meng X, Yin J, Liu X, Chen Z . Cellular basis of itch sensation. Science. 2009; 325(5947):1531-4. PMC: 2786498. DOI: 10.1126/science.1174868. View

Ko M, Husbands S . Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther. 2008; 328(1):193-200. PMC: 2719014. DOI: 10.1124/jpet.108.143925. View

Imamachi N, Park G, Lee H, Anderson D, Simon M, Basbaum A . TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci U S A. 2009; 106(27):11330-5. PMC: 2708751. DOI: 10.1073/pnas.0905605106. View

Stevens Jr W, Jones R, Subramanian G, Metzger T, Ferguson D, Portoghese P . Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. J Med Chem. 2000; 43(14):2759-69. DOI: 10.1021/jm0000665. View

Inan S, Cowan A . Kappa opioid agonists suppress chloroquine-induced scratching in mice. Eur J Pharmacol. 2004; 502(3):233-7. DOI: 10.1016/j.ejphar.2004.09.010. View

Sun Y, Chen Z . A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature. 2007; 448(7154):700-3. DOI: 10.1038/nature06029. View

Takaoka A, Arai I, Sugimoto M, Futaki N, Sakurai T, Honma Y . Role of scratch-induced cutaneous prostaglandin D production on atopic-like scratching behaviour in mice. Exp Dermatol. 2007; 16(4):331-9. DOI: 10.1111/j.1600-0625.2006.00540.x. View

de Castiglione R, Gozzini L . Bombesin receptor antagonists. Crit Rev Oncol Hematol. 1996; 24(2):117-51. DOI: 10.1016/1040-8428(96)00220-x. View

Inan S, Dun N, Cowan A . Inhibitory effect of lidocaine on pain and itch using formalin-induced nociception and 5'-guanidinonaltrindole-induced scratching models in mice: behavioral and neuroanatomical evidence. Eur J Pharmacol. 2009; 616(1-3):141-6. PMC: 2735214. DOI: 10.1016/j.ejphar.2009.06.026. View

10.

Stratford T, Gibbs J, Coy D, Smith G . Fourth ventricular injection of the bombesin receptor antagonist [D-Phe6]bombesin(6-13)methyl ester, but not BW2258U89, increases food intake in rats. Pharmacol Biochem Behav. 1995; 50(3):463-71. DOI: 10.1016/0091-3057(94)00319-e. View

11.

Inan S, Cowan A . Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol Biochem Behav. 2006; 85(1):39-43. DOI: 10.1016/j.pbb.2006.07.004. View

12.

Wikstrom B, Gellert R, Ladefoged S, Danda Y, Akai M, Ide K . Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol. 2005; 16(12):3742-7. DOI: 10.1681/ASN.2005020152. View

13.

Cowan A . Behavioral effects of bombesin. Ann N Y Acad Sci. 1988; 547:204-9. DOI: 10.1111/j.1749-6632.1988.tb23888.x. View

14.

Cowan A, Khunawat P, Zhu X, Gmerek D . Effects of bombesin on behavior. Life Sci. 1985; 37(2):135-45. DOI: 10.1016/0024-3205(85)90416-3. View

15.

Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee D . Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther. 2004; 312(1):220-30. DOI: 10.1124/jpet.104.073668. View

16.

Wakasa Y, Fujiwara A, Umeuchi H, Endoh T, Okano K, Tanaka T . Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sci. 2004; 75(24):2947-57. DOI: 10.1016/j.lfs.2004.05.033. View

17.

Takasaki I, Nojima H, Shiraki K, Kuraishi Y . Specific down-regulation of spinal mu-opioid receptor and reduced analgesic effects of morphine in mice with postherpetic pain. Eur J Pharmacol. 2006; 550(1-3):62-7. DOI: 10.1016/j.ejphar.2006.08.041. View

18.

Nakao K, Ikeda K, Kurokawa T, Togashi Y, Umeuchi H, Honda T . [Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2008; 28(2):75-83. View

19.

Brailoiu G, Dun S, Ohsawa M, Yin D, Yang J, Chang J . KiSS-1 expression and metastin-like immunoreactivity in the rat brain. J Comp Neurol. 2004; 481(3):314-29. DOI: 10.1002/cne.20350. View

20.

Kamichi S, Wada E, Aoki S, Sekiguchi M, Kimura I, Wada K . Immunohistochemical localization of gastrin-releasing peptide receptor in the mouse brain. Brain Res. 2005; 1032(1-2):162-70. DOI: 10.1016/j.brainres.2004.10.068. View